

Title: Dexrazoxane reduces antithrombin activity: Five case reports

Journal Name: Annals of Hematology

Authors: Tomohiro Nagano¹, Kaho Kondo^{1,2}, Akifumi Matsumura^{1,2}, Daigo Niiya¹, Soichiro Fujii¹, Makoto Takeuchi¹

Author's Affiliations:

¹Department of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan

²Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan

Correspondence:


Makoto Takeuchi, Department of Hematology, Japanese Red Cross Okayama Hospital, Address 2-1-1, Aoe, Kita-ku, Okayama-shi, Okayama 700-8607, Japan.

Email: makototake11@gmail.com


Legends for Supplemental Figs. 1–5.

The clinical course of each case (Figs. S1–S5: Cases 1-5, respectively). The antithrombin activities, D-dimer levels, and FDP levels are shown in the line graphs. Each arrow indicates injection of the material described on the left. Extravasation times are marked with crosses. In Figure S1, the continuous injection of etoposide, vincristine, and doxorubicin is shown as a box-like bar.


Rituximab ↓
Etoposide
Vincristine  Extravasation
Doxorubicin
Dexrazoxane ↓ ↓ ↓




Supplemental Fig. 1




Supplemental Fig. 2



Supplemental Fig. 3



Supplemental Fig. 4



Supplemental Fig. 5